Nucleoside transporter subtype expression and function in rat skeletal muscle microvascular endothelial cells.
1. Microvascular endothelial cells (MVECs) form a barrier between circulating metabolites, such as adenosine, and the surrounding tissue. We hypothesize that MVECs have a high capacity for the accumulation of nucleosides, such that inhibition of the endothelial nucleoside transporters (NT) would profoundly affect the actions of adenosine in the microvasculature. 2. We assessed the binding of [(3)H]nitrobenzylmercaptopurine riboside (NBMPR), a specific probe for the inhibitor-sensitive subtype of equilibrative NT (es), and the uptake of [(3)H]formycin B (FB), by MVECs isolated from rat skeletal muscle. The cellular expression of equilibrative (ENT1, ENT2, ENT3) and concentrative (CNT1, CNT2, CNT3) NT subtypes was also determined using both qualitative and quantitative polymerase chain reaction techniques. 3. In the absence of Na(+), MVECs accumulated [(3)H]FB with a V(max) of 21+/-1 pmol microl(-1) s(-1). This uptake was mediated equally by es (K(m) 260+/-70 microm) and ei (equilibrative inhibitor-insensitive; K(m) 130+/-20 microm) NTs. 4. A minor component of Na(+)-dependent cif (concentrative inhibitor-insensitive FB transporter)/CNT2-mediated [(3)H]FB uptake (V(i) 0.008+/-0.005 pmol microl(-1) s(-1) at 10 microm) was also observed at room temperature upon inhibition of ENTs with dipyridamole (2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido-[5,4-d]pyrimidine)/NBMPR. 5. MVECs had 122,000 high-affinity (K(d) 0.10 nm) [(3)H]NBMPR binding sites (representing es transporters) per cell. A lower-affinity [(3)H]NBMPR binding component (K(d) 4.8 nm) was also observed that may be related to intracellular es-like proteins. 6. Rat skeletal muscle MVECs express es/ENT1, ei/ENT2, and cif/CNT2 transporters with characteristics typical of rat tissues. This primary cell culture model will enable future studies on factors influencing NT subtype expression, and the consequent effect on adenosine bioactivity, in the microvasculature.
Archer
Richard G E
RG
Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada.
Pitelka
Václav
V
Hammond
James R
JR
D000818:Animals; D002196:Capillaries / Q000166:cytology / Q000378:metabolism; D002469:Cell Separation; D002478:Cells, Cultured; D017931:DNA Primers; D004109:Dilazep / Q000494:pharmacology; D004176:Dipyridamole / Q000494:pharmacology; D042783:Endothelial Cells / Q000378:metabolism*; D005573:Formycins / Q000378:metabolism; D018482:Muscle, Skeletal / Q000166:cytology / Q000378:metabolism*; D033703:Nucleoside Transport Proteins / Q000096:biosynthesis* / Q000502:physiology*; D010879:Piperazines / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013868:Thioinosine / Q000031:analogs & derivatives* / Q000378:metabolism; D014665:Vasodilator Agents / Q000494:pharmacology
D017931:DNA Primers; D005573:Formycins; D033703:Nucleoside Transport Proteins; D010879:Piperazines; D014665:Vasodilator Agents; C072040:draflazine; D013868:Thioinosine; D004176:Dipyridamole; C034550:formycin; D004109:Dilazep; C001789:4-nitrobenzylthioinosine